



J. David Joyner,
President and CEO CVS Health
1 CVS Drive
Woonsocket RI 02895

Daniel O'Day
Chairman/CEO at Gilead Sciences Inc.
333 Lakeside Drive
Foster City, CA 94404

Dear Mr. Joyner and Mr. O'Day,

PrEP4All and members of the PrEP Users Union, a group consisting entirely of current or former PrEP users, **along with 183 PrEP users and 348 PrEP supporters**, write to you requesting that you move quickly to strike a deal that will allow for ready access to lenacapavir (brand name Yeztugo) as PrEP for individuals linked to CVS Health. Corporate profits, whether for manufacturer or insurer, must not come before ensuring simple, unfettered access to a breakthrough PrEP option that could prove critical for anyone who would benefit from an alternative to daily pills. As the only six-month injectable PrEP option, lenacapavir is in a class of its own and must be treated as its own unique modality. As we have seen with contraception, choice of modality is key for preventive health, and it is essential that insured individuals have access to at least one kind of each HIV preventive modality as part of their coverage plan. A deal must be struck between Gilead and CVS Health as soon as possible. Too often, patients are caught in the middle of wealthy CEOs fighting for more money while the wellbeing of communities is disregarded and seen as irrelevant. As leaders of two companies that purport to [care about health](#) and [ending HIV as an epidemic](#), this is a betrayal of your corporate values, the communities you serve, and the customers who've put their trust in you.

CVS' decision to not cover lenacapavir is quite clearly out of line with the intent of federal guidance on PrEP coverage. Though the [most recent US Preventive Services Task Force recommendation for PrEP](#) was issued before the FDA approval of lenacapavir, the Centers for Medicare and Medicaid Services and the Department of Labor indicated in [follow up guidance](#) that all PrEP options that had been FDA approved at the time should be made available without cost sharing. Advocates have been and will continue to fight for the USPSTF recommendation to be even more specifically inclusive of lenacapavir and for the stringent enforcement of the requirement for full cost coverage. However, given the instability and uncertainty surrounding a Task Force that [could be sabotaged by the anti-science sentiments](#) of the current Health Secretary, your company must, on its own, uphold its responsibility to negotiate a pathway forward to coverage before the guidance is updated. We need CVS to be in alignment with

communities in need of PrEP, not a Health Secretary that willfully disregards decades of research proving that HIV causes AIDS.

Gilead's characteristic price gouging on lenacapavir— \$28,000 per person per year— is similarly out of line for an intervention that [benefitted significantly from taxpayer funded NIH research](#). It is also in stark contrast to the rainbow-washed image of benevolent benefactor and community health partner it presents publicly. Lenacapavir can quite feasibly be [manufactured for around \\$40 per person per year](#); even factoring in additional research and development costs does not remotely justify a 70,000% mark up. Given the company's recent [threats to price gouge AIDS Drug Assistance Programs](#) for HIV treatment, possibly leading to the reinstatement of waitlists for people living with HIV, we are concerned that this same obstinance may also slow the establishment of a deal. Insofar as Gilead's immovability on pricing is proving to be an obstacle to coverage, we urge the company to back away from its usual charge-what-the-market-will-bear approach to profits.

The cost of inaction by your two companies cannot be overstated. In PURPOSE 1, lenacapavir [showed astonishing adherence benefits for cisgender women](#). Whereas previous PrEP trials struggled to show efficacy due to the unique challenges faced by women seeking to take a daily pill, lenacapavir prevented all HIV acquisition in the trial. Improved adherence also led to an amazing [96% reduction in new cases compared to background incidence](#) for cisgender men and transgender and gender nonconforming individuals in PURPOSE 2. The inability of your companies to strike a deal is a direct affront to all communities that may uniquely benefit from a long-acting six-month injectable, particularly cisgender Black women who have thus far been left out of PrEP access despite being significantly more vulnerable to infection compared to White women in America.

As PrEP users, we need and deserve access to taxpayer-funded HIV prevention innovations; corporate dealmaking must not get in the way of that. We urge you both to come quickly to the table and strike a deal that aligns with the intent of USPSTF guidance— create a pathway to lenacapavir as PrEP for CVS Health covered patients that is completely free of cost sharing without the use of prior authorizations or utilization management.

Sincerely,

PrEP4All & the PrEP Users' Union

Current and Former PrEP Users (183)

Saeed A.
Alessandro A.
Joseph A.

Jim A.
John A.
John A.

M A.
George A.
Luiz A.

Aracely A.
Rich B.
Caleb B.
Tara B.
Tara B.
Gabriel B.
Dan B.
Derek B.
Derek B.
Tika B.
Maximillian B.
Louis B.
Beau B.
Jalen B.
Brandon B.
Donald B.
Antuan B.
David B.
Tymothy B.
James C.
Michael C.
Carlos C.
Andrew C.
Jesse C.
Brian C.
Jolanda C.
Arturo C.
Arturo C.
Edward C.
Christopher C.
Sterling D.
Kevin Chadwin D.
Ronald D.
Joelson D.
Lin D.
Juan D.
Ricardo D.
Greg D.
Charlie D.
Daemon D.
Sam D.
Warren E.
Eduardo F.
Dylan F.
Leslie F.
Feliziano F.

Peter F.
Peter F.
Ryan F.
William F.
Angel F.
Eric G.
Christian G.
Derek Scott G.
Grayson G.
Dominic G.
Ronald G.
Eric H.
Andrew H.
Jon H.
Marcos H.
Sloane H.
Eric Robert H.
Brandon J.
Terry J.
Damon L J.
Alec J.
Seth J.
James J.
James J.
John J.
Michael K.
Casey K.
Sean K.
Yuri K.
Chris K.
Chris K.
Loren K.
Jason K.
James M. K.
Ryan K.
Sean L.
Christian L.
Daniel L.
Ron L.
Ronald L.
Michael L.
Josh L.
Andrew L.
William M.
Matthew M.
Kaitlyn M.

Brian M.
Omar M.
Joel M.
Michael M.
Michael M.
Christopher M.
Flo M.
Seth M.
Darren M.
Marco M.
Byron M.
Scott N.
Landon N.
John N.
Amy N.
Brian O.
Maurice O.
Joshua O.
Oswaldo O.
Luis O.
Matt P.
Giovana P.
Travis P.
Nuci P.
John P.
Sandy P.
Charlie P.
Danielle P.
Mark P.
Daniel P.
Scott P.
LLuvia R.
Rodolfo R.
Irwin R.
John R.
Eberr R.
JDaniel R.
William R.
Carlos R.
Nik S.
Francis S.
Dwight S.
James S.
Steven S.
Ryan S.
Cody S.

Philip S.
Samuel S.
Hilary S.
Steven S.
Karl S.
Manny S.
Maxine S.
John S.
Josh S.
Michael S.
Wakefield S.
Dion S.

R T.
John T.
Joseph T.
David T.
Alejandro U.
Damarys V.
Wes W.
Bryan W.
Robert W.
Michael W.
Michael W.
Darren W.

Daniel W.
Mara W.
Robert W.
Latonia W.
Robert W.
Robert W.
Neil W.
Kenneth Y.
Sattie Z.
Liander Z.
Cary Z.
Austin Z.

PrEP Supporters (348)

Barbara A.
Jenna A.
Joan A.
Joan A.
Tyrica A.
Ha A.
JL A.
Gustavo A.
Pat A.
Kevin A.
Kerry A.
Susan B.
Megan B.
Sharon B.
Jorga B.
Amber B.
Faith B.
Charles W B.
Sharon B.
Muse B.
Joan B.
Brooke B.
Jennifer B.
Libby Esther B.
Fireplace B.
Sonya B.
Barbara B.
Esther B.
Eugene B.

Matthew B.
Julia B.
Michele B.
Esther B.
Lorraine B.
Andre B.
Nicholas B.
Traci B.
Thyais B.
Kirsten B.
Elizabeth B.
Lindsey B.
Debra C.
Blair C.
Stacey C.
Sarah C.
Jazmine C.
Alison C.
Alex C.
Alex C.
Bernice C.
Manju C.
Catherine C.
Craig C.
Meredith C.
Jarrett C.
Kenyetta C.
Eliza C.
Jordyn C.

David C.
Alexander C.
Keith D.
Marcele D.
Christy D.
Deann D.
Beth D.
Brooke D.
Elizabeth D.
Phallon D.
Jeffrey D.
Jeffrey D.
Mary D.
Bianca D.
Penny D.
Howard D.
Karen D.
Tanika D.
Laura D.
Ann D.
Kelly D.
Edward D.
Rebekah D.
Paul E.
Jody E.
Nathan E.
Nancy F.
Timothy F.
Gina F.

Carissa F.
Raymond F.
Gail F.
Maureen F.
Remy F.
Cindra F.
Simone F.
Carol F.
Michelle F.
Brenda F.
Joyce F.
S G.
Elisha G.
Daryl G.
Brenda G.
Sandra G.
Jenny G.
Ked G.
Eric G.
Iriebe G.
Zoe G.
Richard G.
Nicola G.
Barbara G.
Nicola G.
Sally G.
Bernardo G.
Kahlil G.
Jackie G.
James G.
Melissa G.
Candice H.
Robert H.
Robert H.
Matthew H.
Susan H.
John H.
Laura H.
Lehman H.
Andrew H.
Dean H.
Teresa H.
Luz H.
Ashleigh H.
Christina H.
Sherri H.

Felicity H.
Jenny H.
John H.
Celeste H.
Franceina H.
Donald H.
Linda H.
Winston H.
Lara I.
Sheryl I.
Timothy J.
Joyce J.
Gerald J.
Becky J.
Rose J.
Rich J.
Virginia J.
Anabel J.
Sharon L J.
Lakita J.
Eric J.
Alfred J.
James J.
Susan J.
Rowen K.
Tracey K.
Murray K.
Shannon K.
Michael K.
Caroline K.
Janet K.
Richard K.
Dennis K.
Dale K.
Laurel K.
Stan K.
Michael L.
Doug L.
Alexis L.
April L.
Allister L.
Logan L.
Megan L.
Gail L.
Adam L.
Teresa L.

Veronica L.
Sharon L.
Susan L.
Genevieve L.
Heidi L.
Amy M.
Frances M.
Wendy M.
Melissa M.
Kimberly M.
Susanna M.
Eric M.
Amanda M.
Maureen M.
Karen M.
Matthew M.
Joan M.
Paul M.
Jo Ann M.
Caephren M.
Megan M.
Marianna M.
Destiny M.
Chase M.
Linda M.
Mary M.
Brent M.
Kent M.
Sofia M.
Fiona M.
Tammy M.
Jade M.
Jerene M.
Moch Endy M.
Jose M.
Lauren M.
Tim M.
Linda M.
Rachel N.
Sue N.
Stewartakasasha N.
Chris N.
Maureen O.
Joel O.
Joel O.
Bruce O.

Elizabeth O.
Christopher O.
Nenet O.
Anne O.
Shane O.
T P.
Sharon P.
Michael P.
Nicole P.
Dhaval P.
Dennis P.
Fay P.
K P.
Janet P.
Samantha P.
Justin P.
Crystal P.
Jen P.
Carolyn P.
Nicole P.
Maria P.
Amy R.
Lindsay R.
Debra R.
John R.
Aaeron R.
Eric R.
Gina R.
RoseMaria R.
Tess R.
Catherine R.
M S.
P S.
Nancy S.
Liz S.
Dorothy S.
Taylor S.
Tom S.
Maritza S.
Crow S.
Steven S.

Myra S.
Luis S.
Elsbet S.
Pamela S.
Linda S.
Sasha S.
Simataa S.
Hilary S.
Elizabeth S.
Kate S.
Siarra S.
Deidra S.
Diambu S.
Bonnie S.
Jaszmene S.
Meta S.
Art S.
Sven S.
Michael S.
Pamela S.
Alex S.
Lars S.
Richard S.
Jim S.
David S.
Cedric S.
M S.
Marsha S.
Paul S.
R T.
R T.
Wajiha T.
Gloria T.
Kimberly T.
Cornelia T.
Tobey T.
Jalisa T.
Michelle T.
Kim T.
Larry T.
Justin T.

JustinT.
Grace U.
Frank V.
Porfirio V.
Jada V.
Susan V.
Ma W.
Renee W.
Sam W.
Clarke W.
Faith W.
Adam W.
Harold W.
Barbara W.
Julene W.
Jennifer W.
Marie W.
Natalie W.
Barry W.
Paul W.
Eric W.
Alice W.
Eric W.
Alice W.
Steve W.
Richard W.
Charles W.
Mara W.
Cat W.
Nancy W.
David W.
Nancy W.
Danielle W.
Robert W.
Richard W.
Lacey W.
Kristin W.
Bridget W.
J Y.
Timothy Z.
Sierra Z.